CNOT3 and neoplasm: Our data also hints of CNOT3 E20K being an activating mutation as it rescues both complementation and intestinal differentiation assays better than wildtype CNOT3. This was unexpected though not unprecedented as both gain-of-function and inactivating mutations in TP53 have been reported to be tumor-promoting [36, 37].